Charles River Laboratories International, Inc. (CRL)

NYQ – Real Time Price. Currency in USD

168.69

+0.23 (0.14%)

At close: May 12, 2026, 4:00 PM EDT

11.05.2026

Charles River (CRL) Reliance on International Sales: What Investors Need to Know

Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

11.05.2026

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.

09.05.2026

Charles River Laboratories International Q1 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.

08.05.2026

LH vs. CRL: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

08.05.2026

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.

07.05.2026

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

07.05.2026

Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)

Charles River Laboratories is downgraded to 'Sell' as shares have rallied 57% in the past year, outpacing fundamentals. Despite Q1 stabilization, organic revenue declined 1.5% and margins compressed, with near-term growth muted and longer-term AI and regulatory risks looming. CRL maintains 2026 EPS guidance of $10.80–$11.30 but trades at 17.5x forward earnings—still at a discount to its history but not considered cheap.

Videos

No Data

There is no data to display

Press releases

11.05.2026

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

07.05.2026

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fiscal first quarter ended April 4, 2026. “Maintaining the momentum of a record fiscal 2025, CRA continued its strong performance into the first quarter of fiscal 2026 as revenue increased by 10.5% year over year to $201.0 million,” said Paul Maleh, CRA's President and Chief Executive Officer. “This re.

07.05.2026

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that its Board of Directors has declared a quarterly cash dividend of $0.57 per common share to be paid on June 12, 2026 to shareholders of record of CRA's common stock as of the close of business on May 26, 2026. The Company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain sub.

07.05.2026

Charles River Laboratories Announces First-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results.

Charles River Laboratories International, Inc. (CRL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Charles River Laboratories International, Inc. (CRL)

Charles River (CRL) Reliance on International Sales: What Investors Need to Know

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Laboratories International Q1 Earnings Call Highlights

LH vs. CRL: Which Stock Is the Better Value Option?

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)

Videos

No Data

Press releases

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

Charles River Laboratories Announces First-Quarter 2026 Results

Charles River (CRL) Reliance on International Sales: What Investors Need to Know

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Laboratories International Q1 Earnings Call Highlights

LH vs. CRL: Which Stock Is the Better Value Option?

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)

Videos

No Data

Press releases

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

Charles River Laboratories Announces First-Quarter 2026 Results

Search stocks

Charles River Laboratories International, Inc. (CRL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Charles River Laboratories International, Inc. (CRL)

Charles River (CRL) Reliance on International Sales: What Investors Need to Know

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Laboratories International Q1 Earnings Call Highlights

LH vs. CRL: Which Stock Is the Better Value Option?

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)

Videos

No Data

Press releases

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

Charles River Laboratories Announces First-Quarter 2026 Results

Charles River (CRL) Reliance on International Sales: What Investors Need to Know

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Laboratories International Q1 Earnings Call Highlights

LH vs. CRL: Which Stock Is the Better Value Option?

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)

Videos

No Data

Press releases

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

Charles River Laboratories Announces First-Quarter 2026 Results